Mechanism of Inhibition of Enveloped Virus Membrane Fusion by the Antiviral Drug Arbidol

Institut de Biologie et Chimie des Protéines, UMR 5086, CNRS, Université de Lyon, IFR128 BioSciences Gerland-Lyon Sud, Lyon, France.
PLoS ONE (Impact Factor: 3.23). 01/2011; 6(1):e15874. DOI: 10.1371/journal.pone.0015874
Source: PubMed


The broad-spectrum antiviral arbidol (Arb) inhibits cell entry of enveloped viruses by blocking viral fusion with host cell membrane. To better understand Arb mechanism of action, we investigated its interactions with phospholipids and membrane peptides. We demonstrate that Arb associates with phospholipids in the micromolar range. NMR reveals that Arb interacts with the polar head-group of phospholipid at the membrane interface. Fluorescence studies of interactions between Arb and either tryptophan derivatives or membrane peptides reconstituted into liposomes show that Arb interacts with tryptophan in the micromolar range. Interestingly, apparent binding affinities between lipids and tryptophan residues are comparable with those of Arb IC50 of the hepatitis C virus (HCV) membrane fusion. Since tryptophan residues of membrane proteins are known to bind preferentially at the membrane interface, these data suggest that Arb could increase the strength of virus glycoprotein's interactions with the membrane, due to a dual binding mode involving aromatic residues and phospholipids. The resulting complexation would inhibit the expected viral glycoprotein conformational changes required during the fusion process. Our findings pave the way towards the design of new drugs exhibiting Arb-like interfacial membrane binding properties to inhibit early steps of virus entry, i.e., attractive targets to combat viral infection.

Download full-text


Available from: Jean-Pierre Lavergne, Sep 29, 2015
55 Reads
  • Source
    • "related compounds . ARB is an antiviral drug which has proved efficient in reducing the duration of the illness during influenza A and B viral infection and its complications . It has demonstrated a broad - spectrum antiviral activity against a number of enveloped and non - enveloped viruses and , in addition , a possible immunomodulatory effect ( Teissier et al . , 2011 ) ."
    [Show abstract] [Hide abstract]
    ABSTRACT: Arbidol is an antiviral drug that have broad-spectrum activity against a number of viral infections. To date, there is no specific data regarding its effects against a herpesvirus. Here the in vitro antiviral effect of ARB and structurally related derivatives were evaluated in HaCat cells on different steps of HSV1 replication: adsorption, entry and post-entry. The simplified pyrrolidine analogue 9a2, showed the best antiviral activity in vitro by reducing the plaque numbers by about 50%, instead of 42% obtained with Arbidol at the same concentration. Furthermore, we have reported that all tested compounds, evaluated for their immunomodulatory activity, showed the ability to reduce the viral protein VP16 and ICP27 and to modify the virus-induced cytokines expression, allowing the host cell a more efficient antiviral response.
    Journal of Medical Microbiology 09/2014; 63(Pt_11). DOI:10.1099/jmm.0.076612-0 · 2.25 Impact Factor
  • Source
    • "This broad spectrum of activity has complicated interpretation of the molecular basis of Arbidol action, for example, the relative importance of interaction with the lipid membrane or with protein components involved in the membrane fusion process. (Teissier et al., 2011). However, Leneva et al. (2009) have shown that in the case of influenza, properties of the HA, in particular the pH of fusion, are major determinants of the sensitivity of virus replication in vitro, indicating that Arbidol inhibits virus entry by interacting directly with HA to stabilize it against the low pH-induced conformational change mediating membrane fusion. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The fusion of virus and endosome membranes is an essential early stage in influenza virus infection. The low pH-induced conformational change which promotes the fusogenic activity of the haemagglutinin (HA) is thus an attractive target as an antiviral strategy. The anti-influenza drug Arbidol is representative of a class of antivirals which inhibits HA-mediated membrane fusion by increasing the acid stability of the HA. In this study two series of indole derivatives structurally related to Arbidol were designed and synthesized to further probe the foundation of its antiviral activity and develop the basis for a structure-activity relationship (SAR). Ethyl 5-(hydroxymethyl)-1-methyl-2-(phenysulphanylmethyl)-1H-indole-3-carboxylate (15) was identified as one of the most potent inhibitors and more potent than Arbidol against certain subtypes of influenza A viruses. In particular, 15 exhibited a much greater affinity and preference for binding group 2 than group 1 HAs, and exerted a greater stabilising effect, in contrast to Arbidol. The results provide the basis for more detailed SAR studies of Arbidol binding to HA; however, the greater affinity for binding HA was not reflected in a comparable increase in antiviral activity of 15, apparently reflecting the complex nature of the antiviral activity of Arbidol and its derivatives.
    Antiviral research 05/2013; 99(2). DOI:10.1016/j.antiviral.2013.05.005 · 3.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The entry of enveloped viruses into their host cells involves several successive steps, each one being amenable to therapeutic intervention. Entry inhibitors act by targeting viral and/or cellular components, through either the inhibition of protein-protein interactions within the viral envelope proteins or between viral proteins and host cell receptors, or through the inhibition of protein-lipid interactions. Interestingly, inhibitors that concentrate into/onto the membrane in order to target a protein involved in the entry process, such as arbidol or peptide inhibitors of the human immunodeficiency virus (HIV), could allow the use of doses compatible with therapeutic requirements. The efficacy of these drugs validates entry as a point of intervention in viral life cycles. Strategies based upon small molecule antiviral agents, peptides, proteins or nucleic acids, would most likely prove efficient in multidrug combinations, in order to inhibit several steps of virus life cycle and prevent disease progression.
    Molecules 01/2011; 16(1):221-50. DOI:10.3390/molecules16010221 · 2.42 Impact Factor
Show more